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Background: CR8 is a second generation inhibitor of cyclin-dependent kinases derived from roscovitine. CR8 was
shown to be 50–100 fold more potent than roscovitine in inducing apoptosis in different tumor cell lines. In the
present investigation, we have established an analytical method for the quantification of CR8 in biological samples
and evaluated its bioavailability, biodistribution and pharmacokinetics in mice.
Methods: A liquid chromatography method utilizing UV-detection was used for the determination of CR8. CR8 was
administered either orally (100 mg/kg) or i.v. (50 mg/kg) and the animals were sacrificed at different time points.
Blood samples and organs were collected, after which the pharmacokinetic parameters were calculated for plasma
and organs.
Results: CR8 was eluted at 5 minutes in the high performance liquid chromatography system used. The LLOQ
detection was 0.10 μg/ml and linearity was observed within the 0.10-10 μg/ml range (r2 > 0.998). The accuracy and
precision were >86%, while the recovery from plasma was >95%. CR8 was stable for 2 months at room
temperature in both solution and plasma. CR8 pharmacokinetics was fitted to a two-compartment open model
after oral administration and to a one compartment model after i.v. injection. The elimination half-life was about
3 hours. Organ exposure to CR8 (expressed as % AUC organ vs. AUC plasma) was highest in liver (205%), adipose
tissue (188%) and kidney (150%) and low in bone marrow (30%) and brain (15%) as compared to plasma. The oral
bioavailability of CR8 was found to be essentially 100%.
Conclusions: We have developed a rapid and simple method for the analysis of CR8. CR8 pharmacokinetics pattern
showed 100% bioavailability, long half-life and limited distribution to brain and bone marrow, which may allow
systemic exposure higher than the IC50 reported for cell death in tumor cell lines. CR8 displays favorable pharmacological
properties and is therefore a good candidate for future clinical studies.
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Roscovitine is a selective cyclin-dependent kinase (CDK)
1, 2, 5, 7, and 9 inhibitor [1-4] shown to be effective
against several tumors. At present, roscovitine is undergo-
ing Phase II clinical trials in cancer patients (non-small
cell lung cancer, nasopharyngeal cancer). The drug has
limited side effects and toxicity compared to conventional
chemotherapy [5]. However, roscovitine is shown to have
a short elimination half-life and rapid metabolism, which* Correspondence: moustapha.hassan@ki.se
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reproduction in any medium, provided the orleads to suboptimal exposure in clinical trials. Recently, 2-
(R)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-
9-isopropylpurine (CR8; Figure 1) was introduced as a sec-
ond generation cyclin-dependent kinase inhibitor derived
from roscovitine [6]. CR8 is shown to be about 50-fold
more potent compared to roscovitine in inducing apoptosis
in different tumor cell lines including ALL and CLL [7].
Several in-vivo and in-vitro studies have reported
promising results due to the high efficacy of CR8.
Bukanov et al. show CR8 to be effective against auto-
somal dominant polycystic kidney disease by blocking
the renal and hepatic cystogenesis in mice [8]. Another
study reports that CR8 can induce apoptotic tumor cell
death in the neuroblastoma cell line, which is one of theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CR8: 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)
benzyl)-9-isopropylpurine (CR8).
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proven to be a neuro-protector in experimental trau-
matic brain injury and has significantly reduced the le-
sion volume in rats subjected to moderate spinal cord
contusion injury [10,11]. Moreover, CR8 is shown to in-
crease the number of surviving neurons after spinal cord
injury and to decrease the posttraumatic elevation of
biochemical markers of apoptosis in an animal model
[12].
Generally, the final effects of drugs in-vivo are
influenced by many factors, such as systemic exposure,
distribution in various organs, metabolism, lipophilicity,
and protein binding. Bettayeb et al. show the optimal
concentrations of CR8 needed to obtain a desirable
pharmacological effect in-vitro in different cell lines to
be about 0.7 μM [7], which is far below that reported for
roscovitine (14.6 μM) [4].
Despite these results obtained in cell cultures, the phar-
macokinetic profile of CR8 needs to be analyzed prior to
further preclinical and possibly clinical investigations. In
the present investigation we have established and validated
an analytical method for the quantitative determination of
CR8 according to standard bioanalytical guidelines. We
have also investigated the pharmacokinetics profile and
the tissue distribution of CR8 in mice. The present results
are encouraging in terms of further development of CR8
as a drug candidate.
Methods
Chemicals and reagents
Tetrahydrofuran and methanol of high performance li-
quid chromatography (HPLC) grade were obtained from
Merck (Darmstadt, Germany), Tween20 and dimethyl
sulfoxide (DMSO) from Sigma-Aldrich (Stockholm,
Sweden). All other reagents and solvents were of HPLC
analytical grade. S-CR8 was dissolved in DMSO as a
75 mg/ml stock solution and was stored at −20°C. Serial
dilutions were prepared from the main stock for the cali-
bration curves, as quality control samples and foradministration to mice. (R)-roscovitine and (S)-CR8
were synthesized as described previously [13].
Instrumentation and chromatographic conditions
The HPLC system consisted of a Gilson 234 auto-injector
equipped with a 100 μl loop, an LKB 2150 pump
(Pharmacia inc., Sweden), an “LDC analytical spectro-
monitor 3200” UV-detector (USA) and a CSW 32 chroma-
tography station integrator. Separation was performed on a
Zorbax SB-CN column (3.5 μm × 4.6 mm × 150 mm) from
Agilent (USA), while the column was maintained at room
temperature during analysis.
The mobile phase consisted of tetrahydrofuran: 25 mM
phosphate buffer pH = 2.6, ionic strength = 0.022 (20:80,
v/v). Flow rate was set at 0.9 ml/min, running time at 8 min
for standard curve and quality controls and at 15 min for
animal samples to elute all the metabolites. Injection vol-
ume was 50 μl and the UV wavelength used was 305 nm.
Standard curves were prepared from spiked pooled human
plasma, and were linear in the range of 0.1 - 10 μg/ml.
Standard solutions and controls
Pooled heparin plasma from healthy donors was obtained
from the Blood Transfusion Center, Karolinska University
Hospital. Serial standard dilutions in 50 mM Hydrochloric
acid were prepared from the stocks for the calibration
curves and for the quality controls.
Working standard solutions of CR8 in plasma at 10, 8,
6, 5, 4, 3, 2, 1, 0.5, 0.25 and 0.1 μg/ml were prepared by
adding 50 μl from the standard stocks to 950 μl plasma
to reach 1 ml containing the final concentrations. The
calibrators were prepared on the day of each run.
Four quality control samples at concentrations of 0.75,
1.5, 3.5 and 7.0 μg/ml were also prepared in triplicate and
stored at room temperature, +4°C and −20°C for stability
testing.
The quality control samples were repeated using
mouse plasma in triplicate using the same concentra-
tions as in human plasma.
Sample preparation from plasma
70 μl plasma was added to 140 μl methanol and vortexed
for 15 sec. Samples were centrifuged at 10000 g for 10 mi-




A selective method should involve no interference from
endogenous compounds, metabolites and/or different
degradation products related to the drug [14]. We con-
firmed that our method involved no such interference
by running blank biological samples from untreated
mice and mice receiving only the drug vehicle [15].
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A calibration curve was constructed from eight standard
points of CR8 at concentrations ranging from 0.1 -
10 μg/ml, including lower limit of quantification
(LLOQ). The peak areas of CR8 were plotted against the
concentrations. Linearity was assessed by a weighted
least-squares regression analysis and a correlation coeffi-
cient (r2) of 0.99 or better was deemed acceptable. The
LLOQ was set as the lowest measurable concentration
with acceptable accuracy and precision not more than
20% of the expected values [16].
Precision and accuracy
The precision of the method was defined as the percent
relative standard deviation (% SD) calculated from tripli-
cate measurements [(standard deviation)/mean value] ×
100. The accuracy was defined as the percent relative
error (% E) of the mean of the replicate measurements
in relation to the theoretical values [(measured value -
nominal value)/nominal value] × 100 [16,17]. Precision
and accuracy were determined by analyzing quality con-
trol samples (QCs) prepared at four concentrations
(0.75, 1.5, 3.5 and 7.0 μg/ml) in pentaplicate on three
consecutive days [18].
Recovery
Absolute recovery is defined as percentage of reference
compound that is measured to the exact amount of
compound added to a blank buffer [15]. Recovery was
computed by comparing responses in triplicate of
extracted low, middle and high QCs (0.75, 1.5 and
7.0 μg/ml, respectively) samples with those of extracted
solvent to which CR8 has been added at the same nom-
inal concentration [14].
Relative recovery is defined as percentage of the amount
of drug measured from the plasma compared to the
amount measured from pure solvent e.g. 50 mM hydro-
chloric acid (HCl) [15]. The low, medium and high con-
trols (0.75, 1.5 and 7.0 μg/ml, respectively) were prepared
in pooled plasma and in 50 mM HCl. Samples were run in
triplicate and recovery was calculated as the percentage of
(plasma peak area/methanol peak area) × 100.
Stability
The stability of CR8 was determined in plasma samples
using concentrations of 0.75, 1.5, 3.5 and 7.0 μg/ml (in
triplicate). The samples were kept at room temperature,
+4°C and −20°C and analyzed twice weekly for 2 months.
Peak areas of all the samples were compared to peak
areas obtained at time zero.
Animals
All experiments in this study were approved by the
Stockholm Southern Ethics Committee for AnimalResearch and were conducted in accordance with the
Animal Protection Law, the Animal Protection Regula-
tion and the Regulation for the Swedish National Board
for Laboratory Animals.
Female BALB/c mice 8–10 weeks old and weighing
18–21 g were obtained from Scanbur, Sollentuna,
Sweden. The mice were allowed to acclimatize to their
surroundings for one week before starting treatment.
The mice were fed pelleted food and water ad libitum.
CR8 was dissolved in DMSO: 50 mM HCl (10:90 v/v).
The first group of mice received i.v. doses of CR8
(50 mg/kg body weight), the second received oral doses
of CR8 (100 mg/kg body weight) and three control mice
received vehicle alone. Three mice were sacrificed at
each time point and blood samples were collected by
cardiac puncture into heparinized tubes at 10, 20, 30,
60 min, 2, 4, 6, 8 h post administration. Blood samples
were centrifuged immediately after collection at 3000 g
for 5 min at 4°C and the plasma was prepared as men-
tioned previously. Supernatants were collected and all
samples were frozen at −20°C directly after preparation
until further analysis by HPLC. Other organs including
liver, spleen, kidneys, brain, adipose tissue and lungs
were removed, washed and snap frozen immediately in
liquid nitrogen. Bone marrow was flushed from both fe-
murs and mononuclear cells were counted and frozen.
The samples were stored at −20°C to avoid any meta-
bolic activity.
Tissue sample preparation
Samples from different organs were homogenized by
probe sonication in sodium perborate (PBS) (1:3 – 1:5
w:v) for 2 min and vortexed for 1 min. 100 μl of the
homogenate was added to 200 μl methanol, vortexed for
1 min and centrifuged at 10000 g for 10 min. 50 μl of
the supernatant were injected into the HPLC system.
Femurs were removed and cleaned; bone marrow was
flushed with 0.3 ml of PBS and single cell suspension was
prepared by gentle flushing through needle and syringe.
Nucleated cells were counted using Türk solution and
bone marrow was stored at −20°C until assay.
Quality control samples were run together with the
corresponding mouse samples in duplicate.
Pharmacokinetics
Parameters including distribution volume of the central
compartment, elimination rate constant, plasma max-
imum concentration and micro constants were esti-
mated. Clearance (Cl) and distribution volume at the
steady state were calculated from the primary parame-
ters. The plasma concentration versus time curves
(AUC) were calculated from the model derived parame-
ters, and the elimination half-lives were calculated from
the slope of the terminal elimination phase. Bone marrow
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109 cells (= approx. 1 g of tissue). The pharmacokinetic
modeling was performed using WinNonlin version 5.2
(Pharsight, USA).
Oral bioavailability (F) defined as the fraction of the oral
administered dose of CR8 that reaches the systemic circu-
lation was calculated according to the following formula:
F ¼ AUC½ po  doseIV
AUC½ IV  dosepo
Calculations and statistics
The peak areas of CR8 were plotted versus the corre-
sponding nominal concentrations of the standards, and
the standard curve was calculated by linear regression.
CR8 concentrations in mouse plasma, organs and quality
control samples were calculated from the resulting
curves. All values are presented as mean ± S.D.
Results
Analysis of CR8
A precise and accurate method was developed to detect
the drug in plasma and tissue samples in order to investi-
gate the pharmacokinetics of CR8. CR8 is a lipophilic
compound; however, due to the presence of the 2-pyridyl
ring attached to the benzyl ring, its lipophilicity is lower
than that of the parent analogue roscovitine. DMSO was
found to be a suitable solvent for very high concentrations
of CR8, and 50 mM HCl was found to be a suitable solv-
ent for standard concentrations. Protein precipitation is
the simplest approach for removing most proteins from
biological samples. Methanol was shown to be better than
acetonitrile in deproteinizing the plasma and extracting
CR8 due to lower number of interfering peaks.
UV absorbance
UV absorbance was determined by running a UV-IVIS
spectrum scan of CR8 dissolved in 50 mM HCl (10 μg/
ml). No interference in the absorption range was detected.
The scan revealed good absorption in the UV 210 nm -
310 nm wavelength ranges, and 305 nm was selected as
the best measurement wavelength to ensure good selectiv-
ity and good sensitivity with a wide range of linear re-
sponse for construction of the standard curves.
Chromatograms and specificity
The CR8 retention time was around 5.26 ± 0.3 min. Se-
lectivity was confirmed by the absence of significant
interfering peaks from endogenous compounds in the
blank plasma at this retention time (Figure 2). Also, no
interference was found from endogenous compounds in
the mouse plasma and tissue samples compared to con-
trol samples (Figure 3).Linearity and limit of quantification
The calibration curve was linear within the ranges of
0.1 μg/ml - 10 μg/ml, and had a correlation coefficient
(r2) ≥ 0.9987 (n = 6). The lower limit of quantification for
CR8 was 0.1 μg/ml in human plasma. The precision and
accuracy at LLOQ were 3.7 and 13.3%, respectively.
Accuracy and precision
The precision and accuracy between and within batch
were always below 13% from the nominal values in all
cases. Precision and accuracy fulfilled the standard guiding
principles for validation of bioanalytical methods, i.e. <
15% for QCs both between batches and within batches
and < 20% for LLOQ [14,16,17,19,20]. No differences were
observed between mouse and human plasma concerning
concentrations in QCs (Table 1).
Recovery
The absolute recovery of CR8 in plasma was 97 ± 6%, 95 ±
5.0% and 98 ± 4% at the concentrations of 0.75, 1.5 and
7.0 μg/ml, respectively, while the relative recoveries of the
drug for the same concentrations in plasma compared to
that obtained from 50 mM HCl were 99 ±3, 103 ± 2 and
96 + 5%, respectively. The recovery from plasma was al-
most completely with low variability. Consequently, plasma
could be a suitable matrix for the regular calibrations
needed to analyze patient/animal materials in future in-
vivo experiments [21].
Stability
The drug proved to be highly stable after 2 months at
room temperature, +4°C or −20°C, with no significant
decrease in the concentration of the QC samples (stabil-
ity found to be approximately 97 ± 3.5%).
CR8 Metabolites
Five CR8 metabolites were separated and found to absorb
UV at the same wavelength as CR8. These metabolites
were named M1-M5 and appeared in the chromatogram
in the following order: M1 at 4.23 minutes, M2 at 5.79 -
minutes, M3 at 8.13 minutes, M4 at 9.95 minutes and M5
at 11.81 minutes (Figure 4). The first and fifth metabolites
(M1 & M5) appeared rapidly with maximum concentration
at 20 minutes and slowly disappeared until 8 hours. The
metabolite M4 increased by time to reach maximum con-
centration at 60 minutes then disappeared. The metabo-
lites M2 and M3 increased and accumulated with time
until 8 hours post administration (Figure 4).
Pharmacokinetics of CR8
To conduct the CR8 pharmacokinetic studies, a simple
HPLC-UV method for the determination of CR8 in hu-
man plasma was developed and validated. The pharma-
cokinetics of CR8 were then investigated in mice and
Figure 2 Quality control samples in human plasma: HPLC chromatograms of blank samples and plasma containing CR8 (QCs) at
concentrations of 1.5, 3.75 and 10.75 μg/mL.
Sallam et al. BMC Pharmacology and Toxicology 2013, 14:50 Page 5 of 9
http://www.biomedcentral.com/bmcpharmacoltoxicol/2050-6511/14/1/50found to fit a two-compartment open model after oral ad-
ministration and a one compartment bolus model after i.v.
administration (Figure 5) using Gauss-Newton criteria.
The CR8 AUC was about 100 μg.hr/ml when 100 mg/
kg was administered orally and about 45 μg.hr/ml when
50 mg/kg was administered intravenously. However, the
estimated Cmax was over 100 μg/ml after i.v. administra-
tion, which is 4 fold higher compared to that observed
after oral administration (Table 2).
Absorption and distribution were rapid and the maximum
concentrations were found at 30 min. Most importantly, the
elimination half-life was estimated to be about 3 hours.
Exposure to concentrations much higher than the
reported average IC50 value (0.7 μM) [7] was found to
last more than 8–10 hours.
The oral bioavailability of CR8 was calculated to be
108 ± 9%.Figure 3 HPLC chromatograms of mouse plasma: The chromatogram
30 min after oral administration.Biodistribution of CR8
CR8 was widely distributed into all tissues, and the time
- concentration curves (AUCs) were fitted to one com-
partment for all tissues (Table 3).
Higher exposure was found in the liver (the tissue/plasma
exposure ratio was 200%), adipose tissue (180%) and kidneys
(150%) compared to that observed as systemic exposure in
plasma. Lung and spleen showed a tissue/plasma ratio of
80% and 50%, respectively (Figure 6) as compared to plasma.
CR8 distribution to the bone marrow
Exposure to CR8 was about 30% in bone marrow com-
pared to in plasma when the concentrations were nor-
malized to tissue weight/g (Figure 6).
This exposure is higher than that reported as IC50 re-
quired for the elimination of leukemic cell lines in about
6 h (data not shown).s contain blank sample, QC (0.75 μg/mL) and CR8 at 20 and
Table 1 Precision and accuracy of the CR8 analysis (n = 3-5 each)
Concentration (μg/ml) Precision (%) Accuracy (%)
Between batch
0.1 (LLOQ) 3.7 −13.3
0.75 (QC1) 7.7 −2.0
1.5 (QC2) 6.9 −3.8
3.5 (QC3) 4.9 −4.4
7.0 (QC4) 3.3 −5.3
Within batch Batch1 Batch2 Batch3 Batch1 Batch2 Batch3
0.1 (LLOQ) 4.2 3.4 4.8 −16 −15.4 −8.5
0.75 (QC1) 1.4 1.8 1.9 5.5 −12.9 −1.2
1.5 (QC2) 1.5 1.7 0.8 4.3 −6.7 3.0
3.5 (QC3) 0.2 0.6 1.1 −9.1 −9.9 −0.6
7.0 (QC4) 0.8 2 1.3 −3.5 −7.4 −4.1
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CR8 was found to pass the blood–brain barrier (BBB)
and the concentration in the brain was about 15% of
that in plasma. Despite this low tissue/plasma ratio, the
concentration reached a value above the reported
CDK5/p25 and casein kinase 1 (CK1) inhibitory IC50
values for more than 6 hours.
Discussion
Recently, the tri-substituted purine CR8 was introduced
as a selective second generation CDK inhibitor analogue
of roscovitine [6,7]. In-vitro studies have shown that
CR8 is 2–4 fold more potent as a CDK inhibitor and
50–100 fold more cytotoxic in tumor cell lines [7]. How-
ever, this enhanced in-vitro activity of CR8 needs to be
confirmed in-vivo in animal models prior to further de-
velopment toward clinical trials in patients. The future
investigation and development of this purine requires anFigure 4 HPLC chromatograms of CR8 and its metabolites. Chromatog
after oral administration, (red) 20 minutes post administration, (blue) 60 mi
(black) blank.accurate analytical method for the quantitative deter-
mination of its pharmacokinetics pattern. In the present
investigation we have developed and validated a new
analytical method for the determination of CR8 in
plasma and tissue samples. Our data showed that the
method is selective and accurate. The acceptance criteria
for the method validation are well in accordance with
internationally accepted criteria [15,18]. Moreover, the
volume required for the analysis is only 50 μl of plasma,
a favorable factor when considering plasma sampling
from small laboratory animals.
The present method was employed for studying the
pharmacokinetics and biodistribution of the drug in
mice. It is of great importance to use a single, suitable
analytical method for both pre-clinical and clinical stud-
ies of newly introduced drugs, such as CDK inhibitors,
that are promising for the treatment of several diseases
including cancer. One important factor is that therams showing CR8 and its five metabolites at different time points
nutes post administration, (green) 8 hours post administration,
Figure 5 Time–plasma concentration curve after PO and IV CR8 to the mouse. Plasma time concentration curve after the oral
administration of 100 mg/kg CR8 where the dashed line is the estimated two compartment model while the open circles are the observed
concentrations. The solid line is the estimated one compartment model after the iv administration of 50 mg/kg CR8, while open triangles
represent the measured concentrations.
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favorable factor for clinical studies where large numbers
of samples are generated and speed of analysis is
important.
The pharmacokinetics profile (especially the oral bio-
availability and the elimination half-life) constitutes a set
of critical factors, strongly influencing whether CR8
should enter preclinical and clinical trials as an anti-
tumor agent. Good oral absorption and appropriate bio-
logical half-life allowing enough exposure to the drug to
produce pharmacological activity and anti-tumor effect
[22], and sufficient elimination allowing minimal tox-
icity, are indeed crucial for further development of an
anti-cancer drug.Table 2 PK parameters of CR8 following single oral
administration at 100 mg/kg and i.v. bolus administration
of 50 mg/kg
PK parameters Oral i.v.
AUC (h.μg/ml) 96.34 ± 10.53 44.35 ± 3.3
Tα (h) 1.3 ± 0.43 0.11 ± 0.01
Tβ (h) 3.1 ± 0.35 2.95 ± 0.11
Cmax (μg/ml) 34.3 ± 1.94 163.9 ± 0.25
Vss (ml) 21 ± 3 44 ± 4
CL (ml/h) 21 ± 2 23 ± 2
Bioavailability (96.43*50)/(44.35*100)*100 = 108%
AUC: Area under time plasma concentration curve.
Tα: First elimination half-life.
Tβ: Terminal elimination half-life.
Cmax: Maximum reached concentration.
Vss: Distribution volume at steady state.
CL: Clearance.Roscovitine, which was introduced as one of the earli-
est CDK inhibitors, is at the present time undergoing
phase II clinical trials in advanced non-small cell lung
cancer and nasopharyngeal cancers [23]. Roscovitine was
shown to have good oral bioavailability and low systemic
toxicity profile [5,24]. However, the anti-tumor re-
sponses observed were modest, most probably a conse-
quence of the drug’s short half-life and rapid metabolism
to inactive metabolites [25]. Generally, exposure to the
drugs is an important factor in the exertion of their anti-
tumor activity. It has been shown that the optimum ef-
fect of roscovitine and the closely related analogue,
N&N1, on tumor cell lines occurs after 8–16 hours of
exposure [26-28]. The systemic exposure to roscovitine
(expressed as AUC in plasma) in adult animals and
humans did not allow a plasma concentration to be
maintained above the reported anti-tumor IC50 (15–
17 μM) for more than 1–2 hours, even when the max-
imum tolerated doses were administered [5]. The only
exception was in young rats, most probably due to im-
mature metabolism [29]. The present results showed
that the systemic exposure expressed as plasma AUC of
CR8 (after single dose administration of 100 mg/kg) was,
for 10 hours, far higher than the anti-tumor IC50 values
found in-vitro (0.3 μg/mL). Thus, second generation an-
alogues of roscovitine might, in addition to increased
cell potency, solve the problem of insufficient exposure
observed in roscovitine. The higher systemic exposure
might in part be explained by the longer half-life (ap-
proximately 3 h) found in female BALB/c mice in the
present study. In this respect CR8 differs from both
roscovitine [27,30] and its close analogue N&N1 [26],
Table 3 Pharmacokinetic parameters of CR8 in different organs following single oral administration of 100 mg/kg
Plasma Liver Adipose tissue Kidney Lung Spleen Bone marrow Brain
AUC (μg.hr/g) 96 197 181 145 77 40 34 14
Beta-HL (hr) 3.10 2.43 2.40 2.62 2.58 2.60 1.98 2.12
Cmax (μg/ml) 34.3 52.4 48.7 36.0 19.3 27.7 10.6 4.1
CL/F 21.0 10.2 11.1 13.8 26.2 20.0 29.5 146.0
V2/F 21.0 35.8 38.2 52.2 96.7 74.5 84.5 447.5
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1 hour when given i.v. at the same dosage.
CR8 was found to have approximately 100% oral
bioavailability, which means the drug is suitable for
oral route intake and that the first pass effect is
negligible.
CR8 distributed rapidly to all the peripheral tissues.
The highest tissue distribution, as compared to plasma
AUC, was found mainly in elimination organs, namely
liver (200%) and kidneys (200%). These results encour-
age the hope that CR8 could perhaps be used to treat
liver and kidney tumors, since it was found to induce
apoptotic cell death in both hepatic and renal tumor cell
lines [7]. Moreover, CR8 showed high distribution to the
adipose tissue (180%) compared to that found in plasma,
a factor that should be considered in dose scheduling in
obese patients.
Surprisingly, CR8 showed higher distribution to the
bone marrow (30%) compared to roscovitine, which was
shown to pass the bone marrow barrier by only 1.5%
[28] while the biodistribution of CR8 in the spleen wasFigure 6 Tissue exposure to CR8 after oral administration of
100 mg/kg to female BALB/c mice. AUC expressed as μg/ml*h in
plasma and as μg/g*h in tissues.about 40%. Moreover, the cytotoxicity of CR8 against
leukemic cell lines has been reported [7]. Altogether,
these results suggest the possible use of CR8 in treating
leukemia and lymphomas. However, the high biodis-
tribution to the bone marrow may cause myelo-
suppression, which was not detected in roscovitine [28].
Further studies are currently ongoing in our laboratory
to explore the cytotoxic effect of CR8 on normal
hematopoietic progenitors. Moreover, we have observed
five different metabolites with different polarities that
have appeared with different kinetics throughout the
CR8 kinetics. Urgent studies are needed to identify and
quantify these metabolites, and to establish their
pharmacological activates and toxicities.
In the present study, we have also shown that CR8
passes the BBB (concentration reached is 15% of that in
plasma) compared to that reported for roscovitine (30%).
This exposure of the brain to CR8 is nevertheless higher
than that required for inhibition of its neuronal targets
like CDK5 and CK1 (IC50 values: 0.12 μM and 0.61 μM,
respectively) [7]. This fact may benefit the drug during
further studies in neurodegenerative animal models and
brain tumor models.
Conclusions
We have developed and validated a simple, fast and se-
lective quantitative analytical method which allowed us
to analyze the pharmacokinetic profile and tissue distri-
bution of the second generation CDK inhibitor CR8.
CR8 was shown to have 100% bioavailability and longer
half-life compared to roscovitine, which may allow
higher systemic exposure than the IC50 values for tumor
cell death induction. The drug passes the BBB at a level
sufficient to reach concentrations able to inhibit neur-
onal kinase targets. Bone marrow exposure was about
30% of that found as systemic exposure, a concentration
potentially sufficient to eliminate leukemic cells. How-
ever, further studies are required to determine the mye-
losuppressive effect and hematotoxicity of CR8. The
present study thus shows favorable pharmacokinetics
properties of CR8 compared to its parent analogue
roscovitine, encouraging further in-vivo studies and con-
sideration of CR8 as a drug candidate.
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